

Carolyn J Crandall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2127015/publications.pdf>

Version: 2024-02-01

114
papers

4,335
citations

116194

36
h-index

139680

61
g-index

115
all docs

115
docs citations

115
times ranked

5483
citing authors

#	ARTICLE	IF	CITATIONS
1	Are serum estrogen concentrations associated with menopausal symptom bother among postmenopausal women? Baseline results from two MsFLASH clinical trials. <i>Maturitas</i> , 2022, 162, 23-30.	1.0	3
2	Repeat Bone Mineral Density Screening Measurement and Fracture Prediction in Older Men: A Prospective Cohort Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3877-e3886.	1.8	7
3	Who should be screened for osteoporosis?. , 2021, , 1501-1510.		0
4	Genetic variants predictive of reproductive aging are associated with vasomotor symptoms in a multiracial/ethnic cohort. <i>Menopause</i> , 2021, 28, 883-892.	0.8	3
5	Cost-effectiveness of sequential daily teriparatide/weekly alendronate compared with alendronate monotherapy for older osteoporotic women with prior vertebral fracture in Japan. <i>Archives of Osteoporosis</i> , 2021, 16, 72.	1.0	6
6	After the initial fracture in postmenopausal women, where do subsequent fractures occur?. <i>EClinicalMedicine</i> , 2021, 35, 100826.	3.2	12
7	Knowledge and Needs of Resident Physicians Regarding Osteoporosis: A Nationwide Survey of Residents. <i>JBMR Plus</i> , 2021, 5, e10524.	1.3	4
8	Cost-effectiveness of zoledronic acid compared with sequential denosumab/alendronate for older osteoporotic women in Japan. <i>Archives of Osteoporosis</i> , 2021, 16, 113.	1.0	13
9	Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 36-52.	3.1	146
10	Osteoporosis Screening in Younger Postmenopausal Women. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 367.	3.8	23
11	Safety of vaginal estrogens: a systematic review. <i>Menopause</i> , 2020, 27, 339-360.	0.8	35
12	Association between post-stroke disability and 5-year hip-fracture risk: The Women's Health Initiative. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 104976.	0.7	9
13	Serial Bone Density Measurement and Incident Fracture Risk Discrimination in Postmenopausal Women. <i>JAMA Internal Medicine</i> , 2020, 180, 1232.	2.6	41
14	The Association of Methotrexate, Sulfasalazine, and Hydroxychloroquine Use With Fracture in Postmenopausal Women With Rheumatoid Arthritis: Findings From the Women's Health Initiative. <i>JBMR Plus</i> , 2020, 4, e10393.	1.3	7
15	Genetic Variation and Hot Flashes: A Systematic Review. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e4907-e4957.	1.8	4
16	Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition. <i>Journal of Orthopaedic Trauma</i> , 2020, 34, e125-e141.	0.7	10
17	Bisphosphonates for Osteopenia in Postmenopausal Women—Reply. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1096.	3.8	0
18	Vasomotor Symptoms and Accelerated Epigenetic Aging in the Women's Health Initiative (WHI). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, 1221-1227.	1.8	16

#	ARTICLE	IF	CITATIONS
19	The Women's Health Initiative: A Landmark Resource for Skeletal Research Since 1992. <i>Journal of Bone and Mineral Research</i> , 2020, 35, 845-860.	3.1	6
20	Predictive Value of DXA Appendicular Lean Mass for Incident Fractures, Falls, and Mortality, Independent of Prior Falls, FRAX, and BMD: Findings from the Women's Health Initiative (WHI). <i>Journal of Bone and Mineral Research</i> , 2020, 36, 654-661.	3.1	18
21	Cumulative Endogenous Estrogen Exposure Is Associated With Postmenopausal Fracture Risk: The Women's Health Initiative Study. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 1260-1269.	3.1	1
22	A Comparison of US and Canadian Osteoporosis Screening and Treatment Strategies in Postmenopausal Women. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 607-615.	3.1	21
23	Strong Bones, Strong Body. <i>Obstetrics and Gynecology Clinics of North America</i> , 2019, 46, 541-552.	0.7	1
24	Bisphosphonates for Postmenopausal Osteoporosis. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 2017.	3.8	47
25	Population-Based Osteoporosis Primary Prevention and Screening for Quality of Care in Osteoporosis, <i>Current Osteoporosis Reports</i> . <i>Current Osteoporosis Reports</i> , 2019, 17, 483-490.	1.5	14
26	Estradiol and Follicle-Stimulating Hormone as Predictors of Onset of Menopause Transition-Related Bone Loss in Pre- and Perimenopausal Women. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 2246-2253.	3.1	23
27	Treatment of Vulvovaginal Atrophy. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 1910.	3.8	6
28	Menopause Management Knowledge in Postgraduate Family Medicine, Internal Medicine, and Obstetrics and Gynecology Residents: A Cross-Sectional Survey. <i>Mayo Clinic Proceedings</i> , 2019, 94, 242-253.	1.4	43
29	Lipoprotein(a) plasma levels, bone mineral density and risk of hip fracture: a post hoc analysis of the Women's Health Initiative, USA. <i>BMJ Open</i> , 2019, 9, e027257.	0.8	2
30	Performance of FRAX and FRAX-Based Treatment Thresholds in Women Aged 40 Years and Older: The Manitoba BMD Registry. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 1419-1427.	3.1	33
31	Do Additional Clinical Risk Factors Improve the Performance of Fracture Risk Assessment Tool (FRAX) Among Postmenopausal Women? Findings From the Women's Health Initiative Observational Study and Clinical Trials. <i>JBMR Plus</i> , 2019, 3, e10239.	1.3	16
32	Cost-Effectiveness of Sequential Teriparatide/Alendronate Versus Alendronate-Alone Strategies in High-Risk Osteoporotic Women in the US: Analyzing the Impact of Generic/Biosimilar Teriparatide. <i>JBMR Plus</i> , 2019, 3, e10233.	1.3	24
33	Persistent vasomotor symptoms and breast cancer in the Women's Health Initiative. <i>Menopause</i> , 2019, 26, 578-587.	0.8	12
34	Association between soft drink consumption and osteoporotic fractures among postmenopausal women: the Women's Health Initiative. <i>Menopause</i> , 2019, 26, 1234-1241.	0.8	8
35	Vaginal estrogen use and chronic disease risk in the Nurses' Health Study. <i>Menopause</i> , 2019, 26, 603-610.	0.8	57
36	Development of a comprehensive health-risk prediction tool for postmenopausal women. <i>Menopause</i> , 2019, 26, 1385-1394.	0.8	7

#	ARTICLE	IF	CITATIONS
37	Impact of Body Weight Dynamics Following Intentional Weight Loss on Fracture Risk: Results from The Action for Health in Diabetes Study. <i>JBMR Plus</i> , 2019, 3, e10086.	1.3	1
38	Characteristics of Self-Reported Sleep and the Risk of Falls and Fractures: The Women's Health Initiative (WHI). <i>Journal of Bone and Mineral Research</i> , 2019, 34, 464-474.	3.1	51
39	Predicting Fracture Risk in Younger Postmenopausal Women: Comparison of the Garvan and FRAX Risk Calculators in the Women's Health Initiative Study. <i>Journal of General Internal Medicine</i> , 2019, 34, 235-242.	1.3	41
40	Postmenopausal Fracture History and Survival After Reproductive Cancer Diagnosis. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky001.	1.4	1
41	Predictors of vasomotor symptoms among breast cancer survivors. <i>Journal of Cancer Survivorship</i> , 2018, 12, 379-387.	1.5	8
42	Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women's Health Initiative Observational Study. <i>Menopause</i> , 2018, 25, 11-20.	0.8	164
43	Bone Health During the Menopause Transition and Beyond. <i>Obstetrics and Gynecology Clinics of North America</i> , 2018, 45, 695-708.	0.7	97
44	Estrogen-alone therapy and invasive breast cancer incidence by dose, formulation, and route of delivery: findings from the WHI observational study. <i>Menopause</i> , 2018, 25, 985-991.	0.8	14
45	Bone Turnover Markers Are Not Associated With Hip Fracture Risk: A Case-Control Study in the Women's Health Initiative. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1199-1208.	3.1	39
46	Optimism, Cynical Hostility, Falls, and Fractures: The Women's Health Initiative Observational Study (WHI-OS). <i>Journal of Bone and Mineral Research</i> , 2017, 32, 221-229.	3.1	9
47	The influence of genetic susceptibility and calcium plus vitamin D supplementation on fracture risk. <i>American Journal of Clinical Nutrition</i> , 2017, 105, 970-979.	2.2	15
48	Time to Clinically Relevant Fracture Risk Scores in Postmenopausal Women. <i>American Journal of Medicine</i> , 2017, 130, 862.e15-862.e23.	0.6	7
49	Gene-Hormone Therapy Interaction and Fracture Risk in Postmenopausal Women. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 1908-1916.	1.8	5
50	Interaction of insulin-like growth factor-I and insulin resistance-related genetic variants with lifestyle factors on postmenopausal breast cancer risk. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 475-495.	1.1	11
51	Associations of Parity, Breastfeeding, and Fractures in the Women's Health Observational Study. <i>Obstetrics and Gynecology</i> , 2017, 130, 171-180.	1.2	26
52	Association of genetic variation in the tachykinin receptor 3 locus with hot flashes and night sweats in the Women's Health Initiative Study. <i>Menopause</i> , 2017, 24, 252-261.	0.8	56
53	Risk of Fracture in Women with Sarcopenia, Low Bone Mass, or Both. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 2673-2678.	1.3	56
54	Screening for Osteoporosis in Older Men: Operating Characteristics of Proposed Strategies for Selecting Men for BMD Testing. <i>Journal of General Internal Medicine</i> , 2017, 32, 1235-1241.	1.3	31

#	ARTICLE	IF	CITATIONS
55	Comparison of clinical outcomes among users of oral and transdermal estrogen therapy in the Women's Health Initiative Observational Study. <i>Menopause</i> , 2017, 24, 1145-1153.	0.8	26
56	Impact of Competing Risk of Mortality on Association of Weight Loss With Risk of Central Body Fractures in Older Men: A Prospective Cohort Study. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 624-632.	3.1	17
57	Letter to the Editor. <i>Endocrine Practice</i> , 2017, 23, 1359.	1.1	0
58	Genetic variants and traits related to insulin-like growth factor-I and insulin resistance and their interaction with lifestyles on postmenopausal colorectal cancer risk. <i>PLoS ONE</i> , 2017, 12, e0186296.	1.1	9
59	Dietary Patterns and Fractures in Postmenopausal Women. <i>JAMA Internal Medicine</i> , 2016, 176, 645.	2.6	102
60	Sodium Intake and Osteoporosis. Findings From the Women's Health Initiative. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1414-1421.	1.8	27
61	Obesity and associated lifestyles modify the effect of glucose metabolism-related genetic variants on impaired glucose homeostasis among postmenopausal women. <i>Genetic Epidemiology</i> , 2016, 40, 520-530.	0.6	10
62	No Increase in Fractures after Stopping Hormone Therapy: Results from the Women's Health Initiative. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 102, jc.2016-3270.	1.8	24
63	Calcium plus vitamin D supplementation and height loss: findings from the Women's Health Initiative Calcium and Vitamin D clinical trial. <i>Menopause</i> , 2016, 23, 1277-1286.	0.8	8
64	Physical Functioning Among Women Aged 80 Years and Older With Previous Fracture. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2016, 71, S31-S41.	1.7	4
65	Baseline age and time to major fracture in younger postmenopausal women. <i>Menopause</i> , 2015, 22, 589-597.	0.8	16
66	Urinary Tract Stones and Osteoporosis: Findings From the Women's Health Initiative. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 2096-2102.	3.1	17
67	Wrist Fracture and Risk of Subsequent Fracture: Findings from the Women's Health Initiative Study. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 2086-2095.	3.1	53
68	Bone Mineral Density as a Predictor of Subsequent Wrist Fractures: Findings From the Women's Health Initiative Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 4315-4324.	1.8	12
69	Parity, lactation, bone strength, and 16-year fracture risk in adult women: Findings from the Study of Women's Health Across the Nation (SWAN). <i>Bone</i> , 2015, 73, 160-166.	1.4	19
70	Associations of Menopausal Vasomotor Symptoms with Fracture Incidence. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 524-534.	1.8	76
71	Postmenopausal weight change and incidence of fracture: post hoc findings from Women's Health Initiative Observational Study and Clinical Trials. <i>BMJ</i> , The, 2015, 350, h25-h25.	3.0	77
72	Risk Assessment Tools for Osteoporosis Screening in Postmenopausal Women: A Systematic Review. <i>Current Osteoporosis Reports</i> , 2015, 13, 287-301.	1.5	31

#	ARTICLE	IF	CITATIONS
73	Comparison of Fracture Risk Prediction by the US Preventive Services Task Force Strategy and Two Alternative Strategies in Women 50–64 Years Old in the Women's Health Initiative. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4514-4522.	1.8	44
74	Insulin Resistance and Bone Strength: Findings From the Study of Midlife in the United States. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 796-803.	3.1	91
75	Osteoporosis Screening in Postmenopausal Women 50 to 64 Years Old: Comparison of US Preventive Services Task Force Strategy and Two Traditional Strategies in the Women's Health Initiative. <i>Journal of Bone and Mineral Research</i> , 2014, 29, 1661-1666.	3.1	69
76	Multisystem Dysregulation and Bone Strength: Findings From the Study of Midlife in the United States. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 1843-1851.	1.8	9
77	Comparative Effectiveness of Pharmacologic Treatments to Prevent Fractures. <i>Annals of Internal Medicine</i> , 2014, 161, 711.	2.0	227
78	Serum Sex Steroid Levels and Longitudinal Changes in Bone Density in Relation to the Final Menstrual Period. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, E654-E663.	1.8	52
79	Childhood socioeconomic status and adult femoral neck bone strength: Findings from the Midlife in the United States Study. <i>Bone</i> , 2013, 56, 320-326.	1.4	16
80	Endogenous Sex Steroid Levels and Cardiovascular Disease in Relation to the Menopause. <i>Endocrinology and Metabolism Clinics of North America</i> , 2013, 42, 227-253.	1.2	69
81	Progestogen levels, progesterone receptor gene polymorphisms, and mammographic density changes. <i>Menopause</i> , 2012, 19, 302-310.	0.8	14
82	Socioeconomic status over the life-course and adult bone mineral density: The Midlife in the U.S. Study. <i>Bone</i> , 2012, 51, 107-113.	1.4	32
83	History of socioeconomic disadvantage and allostatic load in later life. <i>Social Science and Medicine</i> , 2012, 74, 75-83.	1.8	322
84	Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: Results from the Study of Women's Health Across the Nation (SWAN). <i>Journal of Bone and Mineral Research</i> , 2012, 27, 111-118.	3.1	202
85	Breast tenderness after initiation of conjugated equine estrogens and mammographic density change. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 969-979.	1.1	23
86	Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone women's health initiative clinical trials. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 275-285.	1.1	52
87	Association of menopausal vasomotor symptoms with increased bone turnover during the menopausal transition. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 840-849.	3.1	40
88	Change in Follicle-Stimulating Hormone and Estradiol Across the Menopausal Transition: Effect of Age at the Final Menstrual Period. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 746-754.	1.8	282
89	Active, but not passive cigarette smoking was inversely associated with mammographic density. <i>Cancer Causes and Control</i> , 2010, 21, 301-311.	0.8	34
90	Predictors of breast discomfort among women initiating menopausal hormone therapy. <i>Menopause</i> , 2010, 17, 462-470.	0.8	3

#	ARTICLE	IF	CITATIONS
91	New-Onset Breast Tenderness After Initiation of Estrogen Plus Progestin Therapy and Breast Cancer Risk. <i>Archives of Internal Medicine</i> , 2009, 169, 1684.	4.3	19
92	Sex steroid metabolism polymorphisms and mammographic density in pre- and early perimenopausal women. <i>Breast Cancer Research</i> , 2009, 11, R51.	2.2	20
93	Presence of vasomotor symptoms is associated with lower bone mineral density. <i>Menopause</i> , 2009, 16, 239-246.	0.8	56
94	The NAMS competency exam. <i>RN</i> , 2009, 72, 15-7.	0.0	0
95	Menstrual and reproductive factors in relation to mammographic density: the Study of Women's Health Across the Nation (SWAN). <i>Breast Cancer Research and Treatment</i> , 2008, 112, 165-174.	1.1	62
96	Gene Testing to Predict Tamoxifen-Induced Hot Flashes: New Biological Insights. <i>Journal of Clinical Oncology</i> , 2008, 26, 5841-5842.	0.8	1
97	Increases in Serum Estrone Sulfate Level Are Associated with Increased Mammographic Density during Menopausal Hormone Therapy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 1674-1681.	1.1	21
98	Mammographic density in a multiethnic cohort. <i>Menopause</i> , 2007, 14, 891-899.	0.8	81
99	The Association Between Mammographic Breast Density and Bone Mineral Density in the Study of Women's Health Across the Nation. <i>Annals of Epidemiology</i> , 2007, 17, 575-583.	0.9	11
100	Serum prolactin levels are positively associated with mammographic density in postmenopausal women. <i>Breast Cancer Research and Treatment</i> , 2007, 105, 337-346.	1.1	47
101	Is there a positive association between mammographic density and bone mineral density? Authors' response. <i>Breast Cancer Research</i> , 2006, 8, 404.	2.2	0
102	Vasomotor Symptom Prevalence Is Associated with Polymorphisms in Sex Steroid-Metabolizing Enzymes and Receptors. <i>American Journal of Medicine</i> , 2006, 119, S52-S60.	0.6	69
103	Association of New-Onset Breast Discomfort With an Increase in Mammographic Density During Hormone Therapy. <i>Archives of Internal Medicine</i> , 2006, 166, 1578.	4.3	25
104	The Association of Endogenous Sex Steroids and Sex Steroid Binding Proteins with Mammographic Density: Results from the Postmenopausal Estrogen/Progestin Interventions Mammographic Density Study. <i>American Journal of Epidemiology</i> , 2005, 162, 826-834.	1.6	96
105	Positive association between mammographic breast density and bone mineral density in the Postmenopausal Estrogen/Progestin Interventions Study. <i>Breast Cancer Research</i> , 2005, 7, R922-8.	2.2	25
106	Vitamin A Intake and Osteoporosis: A Clinical Review. <i>Journal of Women's Health</i> , 2004, 13, 939-953.	1.5	48
107	Association of breast cancer and its therapy with menopause-related symptoms. <i>Menopause</i> , 2004, 11, 519-530.	0.8	107
108	Low-Dose Estrogen Therapy for Menopausal Women: A Review of Efficacy and Safety. <i>Journal of Women's Health</i> , 2003, 12, 723-747.	1.5	33

#	ARTICLE	IF	CITATIONS
109	Laboratory workup for osteoporosis. <i>Postgraduate Medicine</i> , 2003, 114, 35-44.	0.9	14
110	Combination Treatment of Osteoporosis: A Clinical Review. <i>Journal of Women's Health and Gender-Based Medicine</i> , 2002, 11, 211-224.	1.7	11
111	Vaginal Estrogen Preparations: A Review of Safety and Efficacy for Vaginal Atrophy. <i>Journal of Women's Health</i> , 2002, 11, 857-877.	1.5	58
112	Parathyroid Hormone for Treatment of Osteoporosis. <i>Archives of Internal Medicine</i> , 2002, 162, 2297.	4.3	49
113	Risedronate. <i>Archives of Internal Medicine</i> , 2001, 161, 353.	4.3	42
114	Tolterodine: A Clinical Review. <i>Journal of Women's Health and Gender-Based Medicine</i> , 2001, 10, 735-743.	1.7	19